Roberta Diaz Brinton, Ph.D. is Director of the UA Center for Innovation in Brain Science, (http://cibs.uahs.arizona.edu/). Brinton is internationally recognized as an innovative leader in Alzheimer’s research and development of therapeutics to prevent, delay and treat the disease. She leads multiple National Institutes of Health / Aging grants focused on brain aging and Alzheimer’s disease (http://www.robertabrinton.com/home/). Her latest innovation is development of the first regenerative therapeutic for Alzheimer’s disease, which is currently in clinical testing (https://clinicaltrials.gov/ct2/show/NCT02221622?term=Allopregnanolone&ra...). Brinton has published over 200 scientific reports and holds multiple patents targeting Alzheimer’s disease and neurodegenerative diseases. She serves on Boards of the Alzheimer’s Drug Discovery Foundation and NIH Center for Scientific Review. Among her many recognitions, Dr. Brinton was awarded the Alzheimer’s Drug Discovery Foundation Scientist of the Year, US News and World Report Ten Best Minds and the Presidential Citizens Medal.
My laboratories research focuses on the role of estrogen and bioenergetics in aging and age-associated neurodegeneration as well as the development of regenerative therapeutics. Over the last thirty years my laboratory has demonstrated that ovarian steroids and neurosteroids are key mechanistic regulators of the bioenergetic and regenerative systems of the brain. We observed that a loss of ovarian hormones leads to activation of a sequence of compensatory responses that ultimately lead to development of Alzheimer's pathology. Translationally, we believe that targeting these bioenergetic and regenerative pathways will provide the basis for personalized interventions that can target stages of bioenergetic aging in both the female and male brain to prevent, delay and treat Alzheimer's disease.